Cargando…
Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma
IMPORTANCE: Immune checkpoint blockade (ICB) has improved the survival of patients with advanced melanoma. Durable responses are observed for 40% to 60% of patients, depending on treatment regimens. However, there is still large variability in the response to treatment with ICB, and patients experie...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936383/ https://www.ncbi.nlm.nih.gov/pubmed/36795408 http://dx.doi.org/10.1001/jamaoncol.2022.7753 |
_version_ | 1784890218469392384 |
---|---|
author | Bolte, Laura A. Lee, Karla A. Björk, Johannes R. Leeming, Emily R. Campmans-Kuijpers, Marjo J. E. de Haan, Jacco J. Vila, Arnau Vich Maltez-Thomas, Andrew Segata, Nicola Board, Ruth Harries, Mark Lorigan, Paul de Vries, Elisabeth G. E. Nathan, Paul Fehrmann, Rudolf Bataille, Véronique Spector, Tim D. Hospers, Geke A. P. Weersma, Rinse K. |
author_facet | Bolte, Laura A. Lee, Karla A. Björk, Johannes R. Leeming, Emily R. Campmans-Kuijpers, Marjo J. E. de Haan, Jacco J. Vila, Arnau Vich Maltez-Thomas, Andrew Segata, Nicola Board, Ruth Harries, Mark Lorigan, Paul de Vries, Elisabeth G. E. Nathan, Paul Fehrmann, Rudolf Bataille, Véronique Spector, Tim D. Hospers, Geke A. P. Weersma, Rinse K. |
author_sort | Bolte, Laura A. |
collection | PubMed |
description | IMPORTANCE: Immune checkpoint blockade (ICB) has improved the survival of patients with advanced melanoma. Durable responses are observed for 40% to 60% of patients, depending on treatment regimens. However, there is still large variability in the response to treatment with ICB, and patients experience a range of immune-related adverse events of differing severity. Nutrition, through its association with the immune system and gut microbiome, is a poorly explored but appealing target with potential to improve the efficacy and tolerability of ICB. OBJECTIVE: To investigate the association between habitual diet and response to treatment with ICB. DESIGN, SETTING, AND PARTICIPANTS: This multicenter cohort study (the PRIMM study) was conducted in cancer centers in the Netherlands and UK and included 91 ICB-naive patients with advanced melanoma who were receiving ICB between 2018 and 2021. EXPOSURES: Patients were treated with anti–programmed cell death 1 and anti–cytotoxic T lymphocyte–associated antigen 4 monotherapy or combination therapy. Dietary intake was assessed through food frequency questionnaires before treatment. MAIN OUTCOMES AND MEASURES: Clinical end points were defined as overall response rate (ORR), progression-free survival at 12 months (PFS-12), and immune-related adverse events that were grade 2 or higher. RESULTS: There were a total of 44 Dutch participants (mean [SD] age, 59.43 [12.74] years; 22 women [50%]) and 47 British participants (mean [SD] age, 66.21 [16.63] years; 15 women [32%]). Dietary and clinical data were prospectively collected from 91 patients receiving ICB between 2018 and 2021 for advanced melanoma in the UK and the Netherlands. Logistic generalized additive models revealed positive linear associations between a Mediterranean dietary pattern that was high in whole grains, fish, nuts, fruit, and vegetables and the probability of ORR and PFS-12 (probability of 0.77 for ORR; P = .02; false discovery rate, 0.032; effective degrees of freedom, 0.83; probability of 0.74 for PFS-12; P = .01; false discovery rate, 0.021; effective degrees of freedom, 1.54). CONCLUSIONS AND RELEVANCE: This cohort study found a positive association between a Mediterranean diet, a widely recommended model of healthy eating, and response to treatment with ICB. Large prospective studies from different geographies are needed to confirm the findings and further elucidate the role of diet in the context of ICB. |
format | Online Article Text |
id | pubmed-9936383 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | American Medical Association |
record_format | MEDLINE/PubMed |
spelling | pubmed-99363832023-02-18 Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma Bolte, Laura A. Lee, Karla A. Björk, Johannes R. Leeming, Emily R. Campmans-Kuijpers, Marjo J. E. de Haan, Jacco J. Vila, Arnau Vich Maltez-Thomas, Andrew Segata, Nicola Board, Ruth Harries, Mark Lorigan, Paul de Vries, Elisabeth G. E. Nathan, Paul Fehrmann, Rudolf Bataille, Véronique Spector, Tim D. Hospers, Geke A. P. Weersma, Rinse K. JAMA Oncol Brief Report IMPORTANCE: Immune checkpoint blockade (ICB) has improved the survival of patients with advanced melanoma. Durable responses are observed for 40% to 60% of patients, depending on treatment regimens. However, there is still large variability in the response to treatment with ICB, and patients experience a range of immune-related adverse events of differing severity. Nutrition, through its association with the immune system and gut microbiome, is a poorly explored but appealing target with potential to improve the efficacy and tolerability of ICB. OBJECTIVE: To investigate the association between habitual diet and response to treatment with ICB. DESIGN, SETTING, AND PARTICIPANTS: This multicenter cohort study (the PRIMM study) was conducted in cancer centers in the Netherlands and UK and included 91 ICB-naive patients with advanced melanoma who were receiving ICB between 2018 and 2021. EXPOSURES: Patients were treated with anti–programmed cell death 1 and anti–cytotoxic T lymphocyte–associated antigen 4 monotherapy or combination therapy. Dietary intake was assessed through food frequency questionnaires before treatment. MAIN OUTCOMES AND MEASURES: Clinical end points were defined as overall response rate (ORR), progression-free survival at 12 months (PFS-12), and immune-related adverse events that were grade 2 or higher. RESULTS: There were a total of 44 Dutch participants (mean [SD] age, 59.43 [12.74] years; 22 women [50%]) and 47 British participants (mean [SD] age, 66.21 [16.63] years; 15 women [32%]). Dietary and clinical data were prospectively collected from 91 patients receiving ICB between 2018 and 2021 for advanced melanoma in the UK and the Netherlands. Logistic generalized additive models revealed positive linear associations between a Mediterranean dietary pattern that was high in whole grains, fish, nuts, fruit, and vegetables and the probability of ORR and PFS-12 (probability of 0.77 for ORR; P = .02; false discovery rate, 0.032; effective degrees of freedom, 0.83; probability of 0.74 for PFS-12; P = .01; false discovery rate, 0.021; effective degrees of freedom, 1.54). CONCLUSIONS AND RELEVANCE: This cohort study found a positive association between a Mediterranean diet, a widely recommended model of healthy eating, and response to treatment with ICB. Large prospective studies from different geographies are needed to confirm the findings and further elucidate the role of diet in the context of ICB. American Medical Association 2023-02-16 2023-05 /pmc/articles/PMC9936383/ /pubmed/36795408 http://dx.doi.org/10.1001/jamaoncol.2022.7753 Text en Copyright 2023 Bolte LA et al. JAMA Oncology. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the CC-BY License. |
spellingShingle | Brief Report Bolte, Laura A. Lee, Karla A. Björk, Johannes R. Leeming, Emily R. Campmans-Kuijpers, Marjo J. E. de Haan, Jacco J. Vila, Arnau Vich Maltez-Thomas, Andrew Segata, Nicola Board, Ruth Harries, Mark Lorigan, Paul de Vries, Elisabeth G. E. Nathan, Paul Fehrmann, Rudolf Bataille, Véronique Spector, Tim D. Hospers, Geke A. P. Weersma, Rinse K. Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma |
title | Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma |
title_full | Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma |
title_fullStr | Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma |
title_full_unstemmed | Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma |
title_short | Association of a Mediterranean Diet With Outcomes for Patients Treated With Immune Checkpoint Blockade for Advanced Melanoma |
title_sort | association of a mediterranean diet with outcomes for patients treated with immune checkpoint blockade for advanced melanoma |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9936383/ https://www.ncbi.nlm.nih.gov/pubmed/36795408 http://dx.doi.org/10.1001/jamaoncol.2022.7753 |
work_keys_str_mv | AT boltelauraa associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma AT leekarlaa associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma AT bjorkjohannesr associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma AT leemingemilyr associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma AT campmanskuijpersmarjoje associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma AT dehaanjaccoj associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma AT vilaarnauvich associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma AT maltezthomasandrew associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma AT segatanicola associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma AT boardruth associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma AT harriesmark associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma AT loriganpaul associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma AT devrieselisabethge associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma AT nathanpaul associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma AT fehrmannrudolf associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma AT batailleveronique associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma AT spectortimd associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma AT hospersgekeap associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma AT weersmarinsek associationofamediterraneandietwithoutcomesforpatientstreatedwithimmunecheckpointblockadeforadvancedmelanoma |